Publications by authors named "Barrie Chubb"

Claim this Profile
O
Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.
Peter Rossing, Morten Lindhardt, Christian Klyver Tikkanen, Jyothi Menon, Juliette Cattin, Barrie Chubb

Cardiovasc Diabetol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.
Sasha Berry, Barrie Chubb, Annabel Acs, Edel Falla, Akanksha Verma

J Med Econ· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.
Adie Viljoen, Barrie Chubb, Samuel J P Malkin, Sasha Berry, Barnaby Hunt

Eur J Health Econ· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.
Marc Evans, Barrie Chubb, Samuel J P Malkin, Sasha Berry, Jack Lawson

Diabetes Obes Metab· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal-Bolus Insulin in Type 2 Diabetes.
Ildiko Lingvay, Andrei-Mircea Catarig, Jack Lawson, Barrie Chubb, Anders Gorst-Rasmussen

Diabetes Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment.
Jay H Shubrook, Michael Radin, Sarah N Ali, Barrie Chubb, Kristina DiPietrantonio

Adv Ther· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.
Björn Eliasson, Åsa Ericsson, Adam Fridhammar, Andreas Nilsson, Sofie Persson, Barrie Chubb

Pharmacoecon Open· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.
Richard E Pratley, Andrei-Mircea Catarig, Ildiko Lingvay, Adie Viljoen, Abby Paine, Barrie Chubb

Diabetes Obes Metab· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis.
Barrie Chubb, Palvi Gupta, Jatin Gupta, Solomon Nuhoho, Klaus Kallenbach

Diabetes Ther· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.
Samuel J P Malkin, Barnaby Hunt, Eline L Huisman, Tobias S Grand, Barrie Chubb

Diabetes Res Clin Pract· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Pierre Johansen, Barrie Chubb, Barnaby Hunt, Samuel J P Malkin, Anna Sandberg

Adv Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK.
Stephen C Bain, Brian Bekker Hansen, Barnaby Hunt, Barrie Chubb, William J Valentine

J Med Econ· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
Stephen C Bain, Brian B Hansen, Samuel J P Malkin, Solomon Nuhoho, William J Valentine, Barrie Chubb

Diabetes Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting.
Marc Evans, Roopa Mehta, Jens Gundgaard, Barrie Chubb

Diabetes Ther· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia.
Nebojša Lalić, Monika Russel-Szymczyk, Marina Culic, Christian Klyver Tikkanen, Barrie Chubb

Diabetes Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach.
Richard F Pollock, Barrie Chubb, William J Valentine, Simon Heller

Diabetes Metab Syndr Obes· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus.
Marc Evans, Barrie Chubb, Jens Gundgaard

Diabetes Ther· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.
Melanie J Davies, Divina Glah, Barrie Chubb, Gerasimos Konidaris, Phil McEwan

Pharmacoeconomics· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency of blood glucose testing among insulin-treated diabetes mellitus patients in the United Kingdom.
Won Chan Lee, Elise Smith, Barrie Chubb, Michael Lyng Wolden

J Med Econ· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey.
Marc Evans, Henrik Holm Jensen, Mette Bøgelund, Jens Gundgaard, Barrie Chubb

J Med Econ· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective.
Stewart B Harris, Kamlesh Khunti, Mona Landin-Olsson, Claus B Galbo-Jørgensen, Mette Bøgelund, Barrie Chubb

Patient Prefer Adherence· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost of needlestick injuries associated with insulin administration.
Paul Trueman, Matthew Taylor, Nicole Twena, Barrie Chubb

Br J Community Nurs· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is the future for clinical trials internet-based? A cluster randomized clinical trial.
Jennifer Litchfield, Jenny Freeman, Henrik Schou, Mark Elsley, Robert Fuller, Barrie Chubb

Clin Trials· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis